These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Search MEDLINE/PubMed

  • Title: Protease inhibitors and prevention of cross resistance.
    Author: Levin J.
    Journal: AIDS Treat News; 1995 Oct 06; (no 232):1-3. PubMed ID: 11362875.
    Abstract:
    A controversy has developed, initiated by a paper in the April 1995 issue of Nature, over the use of protease inhibitors among AIDS patients. The article, written by Jon Condra and Emilio Emini, reported that HIV developed resistance to indinavir (Merck & Co.'s protease inhibitor), and all other protease inhibitors as well. In response to the study on Merck's product, Roche released information suggesting that their protease inhibitor, saquinavir, does not cause resistance nearly as quickly or as much. Merck is currently studying the combination of indinavir and AZT, and Abbott Laboratories is examining the effects of AZT, ddC, and ritonavir. These studies imply that optimal multi-drug combination therapy should delay drug resistance as well as cross-resistance. The implications are promising for patients with HIV and AIDS. Pharmaceutical companies are conducting additional studies to develop new reverse transcriptase inhibitors and to determine the effectiveness of the combination of two or more protease inhibitors. Each drug trial demonstrates the relationship between dosing and resistance; patients are advised to adhere completely to dosing instructions.
    [Abstract] [Full Text] [Related] [New Search]